Treats Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive. ANDA 202547, held by Orbion Pharms. Aripiprazole.
As of Nov 16, 2026, ANDA 202547 (Aripiprazole), held by Orbion Pharms, was first approved by FDA on Dec 11, 2017, with 5 approved supplements and 0 published complete response letters.
Aripiprazole orally disintegrating tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole orally disintegrating tablets are an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 11, 2017 | Original application | Approved | None posted |
| Aripiprazole10MG · tablet, orally disintegrating;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet, orally disintegrating;oral | Aripiprazole | Rx |
| Feb 18, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 14, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 1, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 11, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters